Grass Pollen Allergy Clinical Trial
Official title:
Investigation of T-regulatory Cells After Subcutaneous Immunotherapy
The primary endpoint was the induction of T-regulatory cells under s specific subcutaneous
immunotherapy (SCIT). Patients suffering from grass pollen allergy (relevant clinical
symptomes during the pollen season, Skin Prick test diamter >4mm or RAST class II or higher)
were included. The patients were allocated to three study groups:
Group 1: during and directly after SCIT (after completion the 2nd or 3rd year of treatment)
Group 2: completed SCIT more then three years ago Group 3: Patients with clinically relevant
grass pollen allergy without SCIT.
The investigators analyzed the lung function parameters, exhaled NO (eNO) and asked the
patients to record symptoms during the adjacent pollen season. A blood sample was drawn to
analyze the amount of TH1 and TH2 and regulatory T-cells, inflammatory markers(IL-2, IL-5,
IL-10, IL-12/23, TNF-alpha, IFN-gamma) and blocking antibodies (IgG, IgG4).
n/a
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
| Completed |
NCT01445002 -
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
|
Phase 2 | |
| Active, not recruiting |
NCT04502966 -
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
|
Phase 2 | |
| Completed |
NCT00263601 -
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT01538979 -
Phase II Study of Grass Pollen Allergy Vaccine BM32
|
Phase 2 | |
| Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
| Completed |
NCT00264459 -
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
|
Phase 3 | |
| Completed |
NCT01308021 -
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
|
Phase 2 | |
| Completed |
NCT00773240 -
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
|
Phase 3 |